{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:41:41Z","timestamp":1792460501282,"version":"4.5.0"},"reference-count":128,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016221","name":"Rowan University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016221","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R15 CA287337-01"],"award-info":[{"award-number":["1R15 CA287337-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.bcp.2025.117532","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T16:51:00Z","timestamp":1762534260000},"page":"117532","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"P2","title":["Saga of MCL1 inhibitors in multiple myeloma"],"prefix":"10.1016","volume":"243","author":[{"given":"Emily","family":"Nelson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandesh P.","family":"Telang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tulin","family":"Budak-Alpdogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subash C.","family":"Jonnalagadda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep K.","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2767-2929","authenticated-orcid":false,"given":"Manoj K.","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.bcp.2025.117532_b0005","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am. J. Hematol."},{"issue":"2","key":"10.1016\/j.bcp.2025.117532_b0010","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3390\/cancers13020256","article-title":"Gain\/amplification of chromosome arm 1q21 in multiple myeloma","volume":"13","author":"Hanamura","year":"2021","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.bcp.2025.117532_b0015","first-page":"2950","article-title":"Multiple myeloma with t (11; 14): unique biology and evolving landscape","volume":"12","author":"Bal","year":"2022","journal-title":"Am. J. Cancer Res."},{"issue":"4","key":"10.1016\/j.bcp.2025.117532_b0020","doi-asserted-by":"crossref","first-page":"606","DOI":"10.3390\/cells11040606","article-title":"Autologous stem cell transplantation in multiple myeloma: where are we and where do we want to go?","volume":"11","author":"Mor\u00e8","year":"2022","journal-title":"Cells"},{"issue":"11","key":"10.1016\/j.bcp.2025.117532_b0025","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1158\/0008-5472.CAN-06-4322","article-title":"Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma","volume":"67","author":"Gomez-Bougie","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2025.117532_b0030","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ctrv.2018.09.001","article-title":"Drug resistance in multiple myeloma","volume":"70","author":"Robak","year":"2018","journal-title":"Cancer Treat. Rev."},{"issue":"6","key":"10.1016\/j.bcp.2025.117532_b0035","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.bcp.2025.117532_b0040","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.bcp.2025.117532_b0045","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41571-020-0427-6","article-title":"CAR T cell therapies for patients with multiple myeloma","volume":"18","author":"Mikkilineni","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.bcp.2025.117532_b0050","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/nrc883","article-title":"The Bcl2 family: regulators of the cellular life-or-death switch","volume":"2","author":"Cory","year":"2002","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.bcp.2025.117532_b0055","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/febs.14186","article-title":"Bax, Bak and beyond\u2014mitochondrial performance in apoptosis","volume":"285","author":"Pe\u00f1a-Blanco","year":"2018","journal-title":"FEBS J."},{"issue":"20","key":"10.1016\/j.bcp.2025.117532_b0060","doi-asserted-by":"crossref","first-page":"6209","DOI":"10.1111\/febs.16136","article-title":"Understanding MCL1: from cellular function and regulation to pharmacological inhibition","volume":"289","author":"Sancho","year":"2022","journal-title":"FEBS J."},{"issue":"6","key":"10.1016\/j.bcp.2025.117532_b0065","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a041046","article-title":"The mitochondrial pathway of apoptosis part II: the BCL-2 protein family","volume":"14","author":"Green","year":"2022","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.bcp.2025.117532_b0070","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.864874","article-title":"Structural details of BH3 motifs and BH3-mediated interactions: an updated perspective","volume":"9","author":"Sora","year":"2022","journal-title":"Front. Mol. Biosci."},{"issue":"11","key":"10.1016\/j.bcp.2025.117532_b0075","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/s41422-019-0231-y","article-title":"BH3-only proteins target BCL-xL\/MCL-1, not BAX\/BAK, to initiate apoptosis","volume":"29","author":"Huang","year":"2019","journal-title":"Cell Res."},{"key":"10.1016\/j.bcp.2025.117532_b0080","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.574338","article-title":"The multifaceted roles of the BCL-2 family member BOK","volume":"8","author":"Naim","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"issue":"4","key":"10.1016\/j.bcp.2025.117532_b0085","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/s41419-020-2417-0","article-title":"BCL-w: apoptotic and non-apoptotic role in health and disease","volume":"11","author":"Hartman","year":"2020","journal-title":"Cell Death Dis."},{"issue":"15","key":"10.1016\/j.bcp.2025.117532_b0090","doi-asserted-by":"crossref","first-page":"11092","DOI":"10.1074\/jbc.275.15.11092","article-title":"Structural basis of BFL-1 for its interaction with BAX and its anti-apoptotic action in mammalian and yeast cells","volume":"275","author":"Cowan-Jacob","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2025.117532_b0095","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.699629","article-title":"Mcl-1 inhibition: managing malignancy in multiple myeloma","volume":"12","author":"Al-Odat","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117532_b0100","article-title":"Selective inhibitors of Mcl-1 with potent activity against multiple myeloma patient cells and animal xenografts","volume":"73(8_Supplement):3438-","author":"Azmi","year":"2013","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.bcp.2025.117532_b0105","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/sj.leu.2403784","article-title":"Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival","volume":"19","author":"Wuilleme-Toumi","year":"2005","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.bcp.2025.117532_b0110","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/s42003-021-02564-6","article-title":"The multiple mechanisms of MCL1 in the regulation of cell fate","volume":"4","author":"Widden","year":"2021","journal-title":"Commun. Biol."},{"issue":"2","key":"10.1016\/j.bcp.2025.117532_b0115","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3109\/10428194.2010.537795","article-title":"Clinical and biological features of t (4; 14) multiple myeloma: a prospective study","volume":"52","author":"Karlin","year":"2011","journal-title":"Leuk. Lymphoma"},{"issue":"13","key":"10.1016\/j.bcp.2025.117532_b0120","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1182\/blood.2022016212","article-title":"The location of the t (4; 14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM","volume":"141","author":"Stong","year":"2023","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bcp.2025.117532_b0125","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/ajh.25758","article-title":"A multicenter retrospective study of 223 patients with t (14; 16) in multiple myeloma","volume":"95","author":"Goldman-Mazur","year":"2020","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.bcp.2025.117532_b0130","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41408-023-00933-4","article-title":"Prognostic impact of translocation t (14; 16) in multiple myeloma according to the presence of additional genetic lesions","volume":"13","author":"Schavgoulidze","year":"2023","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.bcp.2025.117532_b0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-018-4602-4","article-title":"MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma","volume":"18","author":"Qiang","year":"2018","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.bcp.2025.117532_b0140","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-019-0191-y","article-title":"Natural history of multiple myeloma with de novo del (17p)","volume":"9","author":"Lakshman","year":"2019","journal-title":"Blood Cancer J."},{"issue":"6","key":"10.1016\/j.bcp.2025.117532_b0145","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/s41375-018-0036-x","article-title":"Targeting MYC in multiple myeloma","volume":"32","author":"Jovanovi\u0107","year":"2018","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.bcp.2025.117532_b0150","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1182\/blood.2022017863","article-title":"Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del (1p32) remains a strong prognostic factor","volume":"141","author":"Schavgoulidze","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bcp.2025.117532_b0155","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13045-021-01079-1","article-title":"Targeting MCL-1 in cancer: current status and perspectives","volume":"14","author":"Wang","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2025.117532_b0160","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.201600251","article-title":"Fragment\u2010Based Design, Synthesis, and Biological Evaluation of 1\u2010Substituted\u2010indole\u20102\u2010carboxylic Acids as Selective Mcl\u20101 Inhibitors","volume":"350","author":"Wang","year":"2017","journal-title":"Arch. Pharm."},{"issue":"4","key":"10.1016\/j.bcp.2025.117532_b0165","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1021\/jm101181u","volume":"54","author":"Zhang","year":"2011","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bcp.2025.117532_b0170","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1021\/acs.jmedchem.9b00983","article-title":"Hot-spots of Mcl-1 protein: miniperspective","volume":"63","author":"Denis","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117532_b0175","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.pharmthera.2014.08.003","article-title":"Small molecule Mcl-1 inhibitors for the treatment of cancer","volume":"145","author":"Belmar","year":"2015","journal-title":"Pharmacol. Ther."},{"issue":"8","key":"10.1016\/j.bcp.2025.117532_b0180","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/nchembio.391","article-title":"The MCL-1 BH3 helix is an exclusive MCL-1 inhibitor and apoptosis sensitizer","volume":"6","author":"Stewart","year":"2010","journal-title":"Nat. Chem. Biol."},{"issue":"2","key":"10.1016\/j.bcp.2025.117532_b0185","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/s41418-019-0486-3","article-title":"Saga of Mcl-1: regulation from transcription to degradation","volume":"27","author":"Senichkin","year":"2020","journal-title":"Cell Death & Differentiation."},{"key":"10.1016\/j.bcp.2025.117532_b0190","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.taap.2018.09.008","article-title":"The suppressive effect of arsenic trioxide on TET2-FOXP3-Lyn-Akt axis-modulated MCL1 expression induces apoptosis in human leukemia cells","volume":"358","author":"Chen","year":"2018","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"11","key":"10.1016\/j.bcp.2025.117532_b0195","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1080\/10428194.2017.1421760","article-title":"PI3K\/AKT\/mTOR pathway in multiple myeloma: from basic biology to clinical promise","volume":"59","author":"Ramakrishnan","year":"2018","journal-title":"Leuk. Lymphoma"},{"issue":"14","key":"10.1016\/j.bcp.2025.117532_b0200","doi-asserted-by":"crossref","first-page":"8240","DOI":"10.1093\/nar\/gkac631","article-title":"mRNA-and factor-driven dynamic variability controls eIF4F-cap recognition for translation initiation","volume":"50","author":"\u00c7etin","year":"2022","journal-title":"Nucleic Acids Res."},{"issue":"9","key":"10.1016\/j.bcp.2025.117532_b0205","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1038\/s41418-018-0244-y","article-title":"By reducing global mRNA translation in several ways, 2-deoxyglucose lowers MCL-1 protein and sensitizes hemopoietic tumor cells to BH3 mimetic ABT737","volume":"26","author":"Tailler","year":"2019","journal-title":"Cell Death & Differentiation."},{"issue":"1","key":"10.1016\/j.bcp.2025.117532_b0210","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1146\/annurev-pharmtox-010611-134537","article-title":"AMPK and mTOR in cellular energy homeostasis and drug targets","volume":"52","author":"Inoki","year":"2012","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"14","key":"10.1016\/j.bcp.2025.117532_b0215","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1111\/febs.13472","article-title":"Attacking cancer's Achilles heel: antagonism of anti\u2010apoptotic BCL\u20102 family members","volume":"283","author":"Opferman","year":"2016","journal-title":"FEBS J."},{"issue":"24","key":"10.1016\/j.bcp.2025.117532_b0220","doi-asserted-by":"crossref","first-page":"36353","DOI":"10.18632\/oncotarget.9217","article-title":"DNA damaging agent-induced apoptosis is regulated by MCL-1 phosphorylation and degradation mediated by the Noxa\/MCL-1\/CDK2 complex","volume":"7","author":"Nakajima","year":"2016","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.bcp.2025.117532_b0225","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.bbrc.2011.08.118","article-title":"Noxa controls Mule-dependent Mcl-1 ubiquitination through the regulation of the Mcl-1\/USP9X interaction","volume":"413","author":"Gomez-Bougie","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2","key":"10.1016\/j.bcp.2025.117532_b0230","doi-asserted-by":"crossref","first-page":"181","DOI":"10.15252\/emmm.201606684","article-title":"HUWE 1 is a critical colonic tumour suppressor gene that prevents MYC signalling, DNA damage accumulation and tumour initiation","volume":"9","author":"Myant","year":"2017","journal-title":"EMBO Mol. Med."},{"issue":"6","key":"10.1016\/j.bcp.2025.117532_b0235","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.molcel.2006.02.009","article-title":"Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1","volume":"21","author":"Maurer","year":"2006","journal-title":"Mol. Cell"},{"issue":"7336","key":"10.1016\/j.bcp.2025.117532_b0240","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/nature09732","article-title":"SCFFBW7 regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction","volume":"471","author":"Inuzuka","year":"2011","journal-title":"Nature"},{"issue":"14","key":"10.1016\/j.bcp.2025.117532_b0245","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1038\/emboj.2010.112","article-title":"Phosphorylation of Mcl\u20101 by CDK1\u2013cyclin B1 initiates its Cdc20\u2010dependent destruction during mitotic arrest","volume":"29","author":"Harley","year":"2010","journal-title":"EMBO J."},{"issue":"15","key":"10.1016\/j.bcp.2025.117532_b0250","doi-asserted-by":"crossref","first-page":"6109","DOI":"10.1158\/0008-5472.CAN-08-0579","article-title":"Down-regulation of myeloid cell leukemia-1 through inhibiting Erk\/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer","volume":"68","author":"Ding","year":"2008","journal-title":"Cancer Res."},{"issue":"7277","key":"10.1016\/j.bcp.2025.117532_b0255","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nature08646","article-title":"Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival","volume":"463","author":"Schwickart","year":"2010","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.bcp.2025.117532_b0260","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1073\/pnas.90.8.3516","article-title":"MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2","volume":"90","author":"Kozopas","year":"1993","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"14","key":"10.1016\/j.bcp.2025.117532_b0265","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1111\/febs.14505","article-title":"Phosphorylation alters Bim\u2010mediated Mcl\u20101 stabilization and priming","volume":"285","author":"Conage-Pough","year":"2018","journal-title":"FEBS J."},{"issue":"1","key":"10.1016\/j.bcp.2025.117532_b0270","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1101\/gad.14.1.23","article-title":"Mcl-1 deficiency results in peri-implantation embryonic lethality","volume":"14","author":"Rinkenberger","year":"2000","journal-title":"Genes Dev."},{"issue":"5712","key":"10.1016\/j.bcp.2025.117532_b0275","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1126\/science.1106114","article-title":"Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells","volume":"307","author":"Opferman","year":"2005","journal-title":"Science"},{"issue":"24","key":"10.1016\/j.bcp.2025.117532_b0280","doi-asserted-by":"crossref","first-page":"6068","DOI":"10.1523\/JNEUROSCI.4940-07.2008","article-title":"Mcl-1 is a key regulator of apoptosis during CNS development and after DNA damage","volume":"28","author":"Arbour","year":"2008","journal-title":"J. Neurosci."},{"issue":"14","key":"10.1016\/j.bcp.2025.117532_b0285","first-page":"1945","article-title":"Requirement for antiapoptotic MCL-1 during early erythropoiesis","volume":"137","author":"Turnis","year":"2021","journal-title":"Blood, the Journal of the American Society of Hematology."},{"issue":"11","key":"10.1016\/j.bcp.2025.117532_b0290","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.4161\/auto.26168","article-title":"MCL1 is critical for mitochondrial function and autophagy in the heart","volume":"9","author":"Thomas","year":"2013","journal-title":"Autophagy"},{"issue":"6764","key":"10.1016\/j.bcp.2025.117532_b0295","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1126\/science.adw1836","article-title":"Relative importance of the anti-apoptotic versus apoptosis-unrelated functions of MCL-1 in vivo","volume":"389","author":"Brinkmann","year":"2025","journal-title":"Science"},{"issue":"6967","key":"10.1016\/j.bcp.2025.117532_b0300","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nature02067","article-title":"Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1","volume":"426","author":"Opferman","year":"2003","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bcp.2025.117532_b0305","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1172\/JCI92742","article-title":"Targeting Mcl-1 enhances DNA replication stress sensitivity to cancer therapy","volume":"128","author":"Chen","year":"2018","journal-title":"J. Clin. Invest."},{"issue":"9","key":"10.1016\/j.bcp.2025.117532_b0310","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1038\/sj.onc.1200927","article-title":"Induction of BCL2 family member MCL1 as an early response to DNA damage","volume":"14","author":"Zhan","year":"1997","journal-title":"Oncogene"},{"issue":"11","key":"10.1016\/j.bcp.2025.117532_b0315","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1038\/cdd.2010.56","article-title":"ATM-dependent expression of IEX-1 controls nuclear accumulation of Mcl-1 and the DNA damage response","volume":"17","author":"Pawlikowska","year":"2010","journal-title":"Cell Death & Differentiation."},{"issue":"8","key":"10.1016\/j.bcp.2025.117532_b0320","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1091\/mbc.e07-11-1171","article-title":"An essential role for MCL-1 in ATR-mediated CHK1 phosphorylation","volume":"19","author":"Jamil","year":"2008","journal-title":"Mol. Biol. Cell"},{"issue":"1","key":"10.1016\/j.bcp.2025.117532_b0325","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/cr.2007.111","article-title":"Regulation of DNA double-strand break repair pathway choice","volume":"18","author":"Shrivastav","year":"2008","journal-title":"Cell Res."},{"issue":"14","key":"10.1016\/j.bcp.2025.117532_b0330","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.4161\/cc.9.14.12354","article-title":"MCL-1 localizes to sites of DNA damage and regulates DNA damage response","volume":"9","author":"Jamil","year":"2010","journal-title":"Cell Cycle"},{"issue":"6","key":"10.1016\/j.bcp.2025.117532_b0335","doi-asserted-by":"crossref","first-page":"561","DOI":"10.4161\/auto.4713","article-title":"Differential interactions between Beclin 1 and Bcl-2 family members","volume":"3","author":"Erlich","year":"2007","journal-title":"Autophagy"},{"issue":"1","key":"10.1016\/j.bcp.2025.117532_b0340","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3390\/biology9010004","article-title":"The role of Beclin 1-dependent autophagy in cancer","volume":"9","author":"Vega-Rub\u00edn-de-Celis","year":"2019","journal-title":"Biology"},{"issue":"2","key":"10.1016\/j.bcp.2025.117532_b0345","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/emboj.2010.327","article-title":"MCL\u20101 is a stress sensor that regulates autophagy in a developmentally regulated manner","volume":"30","author":"Germain","year":"2011","journal-title":"EMBO J."},{"issue":"2","key":"10.1016\/j.bcp.2025.117532_b0350","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1006\/geno.1994.1523","article-title":"Human and mouse chromosomal mapping of the myeloid cell leukemia-1 gene: MCL1 maps to human chromosome 1q21, a region that is frequently altered in preneoplastic and neoplastic disease","volume":"23","author":"Craig","year":"1994","journal-title":"Genomics"},{"issue":"11","key":"10.1016\/j.bcp.2025.117532_b0355","first-page":"3527","article-title":"The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1","volume":"8","author":"Gojo","year":"2002","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.bcp.2025.117532_b0360","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1182\/blood-2003-03-0970","article-title":"Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels","volume":"102","author":"van de Donk","year":"2003","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bcp.2025.117532_b0365","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1021\/jm301448p","article-title":"Discovery of potent myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods and structure-based design","volume":"56","author":"Friberg","year":"2013","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.bcp.2025.117532_b0370","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1021\/acs.jmedchem.5b01913","article-title":"Bcl-2\/MDM2 dual inhibitors based on universal pyramid-like \u03b1-helical mimetics","volume":"59","author":"Wang","year":"2016","journal-title":"J. Med. Chem."},{"issue":"15","key":"10.1016\/j.bcp.2025.117532_b0375","doi-asserted-by":"crossref","first-page":"6913","DOI":"10.1021\/acs.jmedchem.9b00134","article-title":"Structure-guided discovery of a selective Mcl-1 inhibitor with cellular activity","volume":"62","author":"Szl\u00e1vik","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117532_b0380","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ejmech.2018.01.076","article-title":"Small-molecule Mcl-1 inhibitors: Emerging anti-tumor agents","volume":"146","author":"Wan","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117532_b0385","doi-asserted-by":"crossref","first-page":"e1810","DOI":"10.1038\/cddis.2015.168","article-title":"First MCL-1-selective BH3 mimetics as potential therapeutics for targeted treatment of cancer","volume":"6","author":"Besbes","year":"2015","journal-title":"Cell Death Dis."},{"issue":"11","key":"10.1016\/j.bcp.2025.117532_b0390","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1002\/cmdc.202100011","article-title":"Drimane Derivatives as the first examples of Covalent BH3 Mimetics that Target MCL\u20101","volume":"16","author":"Daressy","year":"2021","journal-title":"ChemMedChem"},{"issue":"12","key":"10.1016\/j.bcp.2025.117532_b0395","first-page":"5430","article-title":"Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma","volume":"109","author":"Trudel","year":"2007","journal-title":"Blood, the Journal of the American Society of Hematology."},{"key":"10.1016\/j.bcp.2025.117532_b0400","series-title":"Clinical Perspectives and Targeted Therapies in Apoptosis: Drug Discovery, Drug delivery, and Disease Prevention","author":"Sodhi","year":"2020"},{"key":"10.1016\/j.bcp.2025.117532_b0405","article-title":"Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)","volume":"6(1):e1590-e","author":"Leverson","year":"2015","journal-title":"Cell Death Dis."},{"issue":"6","key":"10.1016\/j.bcp.2025.117532_b0410","article-title":"The MCL-1 inhibitor S63845: an exciting new addition to the armoury of anti-cancer agents","volume":"2","author":"Powell","year":"2017","journal-title":"Journal of Xiangya Medicine."},{"issue":"10","key":"10.1016\/j.bcp.2025.117532_b0415","doi-asserted-by":"crossref","first-page":"4166","DOI":"10.1021\/jm1001265","article-title":"BI-97C1, an optically pure Apogossypol derivative as pan-active inhibitor of antiapoptotic B-cell lymphoma\/leukemia-2 (Bcl-2) family proteins","volume":"53","author":"Wei","year":"2010","journal-title":"J. Med. Chem."},{"issue":"23","key":"10.1016\/j.bcp.2025.117532_b0420","doi-asserted-by":"crossref","first-page":"5351","DOI":"10.1182\/blood.V126.23.5351.5351","article-title":"Targeting cancer stem cell survival in plasma cell leukemia with a pan-BCL2 inhibitor","volume":"126","author":"Lazzari","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2025.117532_b0425","article-title":"Sabutoclax (BI97C1) and BI112D1, putative inhibitors of MCL-1, induce mitochondrial fragmentation either upstream of or independent of apoptosis","volume":"15(5):568-IN22","author":"Varadarajan","year":"2013","journal-title":"Neoplasia"},{"issue":"6","key":"10.1016\/j.bcp.2025.117532_b0430","doi-asserted-by":"crossref","first-page":"557","DOI":"10.4161\/cib.21554","article-title":"Anti-cancer drug discovery and development: Bcl-2 family small molecule inhibitors","volume":"5","author":"Liu","year":"2012","journal-title":"Commun. Integr. Biol."},{"key":"10.1016\/j.bcp.2025.117532_b0435","article-title":"Maritoclax induces apoptosis in acute myeloid leukemia cells with elevated Mcl-1 expression","volume":"15(8):1077-86","author":"Doi","year":"2014","journal-title":"Cancer Biol. Ther."},{"issue":"11","key":"10.1016\/j.bcp.2025.117532_b0440","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0078570","article-title":"Proteasomal degradation of Mcl-1 by maritoclax induces apoptosis and enhances the efficacy of ABT-737 in melanoma cells","volume":"8","author":"Pandey","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2025.117532_b0445","article-title":"Discovery of marinopyrrole a (maritoclax) as a selective Mcl-1 antagonist that overcomes ABT-737 resistance by binding to and targeting Mcl-1 for proteasomal degradation","volume":"287(13):10224-35","author":"Doi","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.bcp.2025.117532_b0450","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.chembiol.2012.07.018","article-title":"A competitive stapled peptide screen identifies a selective small molecule that overcomes MCL-1-dependent leukemia cell survival","volume":"19","author":"Cohen","year":"2012","journal-title":"Chem. Biol."},{"issue":"3","key":"10.1016\/j.bcp.2025.117532_b0455","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41419-019-1426-3","article-title":"Confounding off-target effects of BH3 mimetics at commonly used concentrations: MIM1, UMI-77, and A-1210477","volume":"10","author":"Mallick","year":"2019","journal-title":"Cell Death Dis."},{"issue":"21","key":"10.1016\/j.bcp.2025.117532_b0460","doi-asserted-by":"crossref","first-page":"6642","DOI":"10.1016\/j.bmc.2013.08.017","article-title":"Hydroxyquinoline-derived compounds and analoguing of selective Mcl-1 inhibitors using a functional biomarker","volume":"21","author":"Richard","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117532_b0465","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s10549-018-5022-5","article-title":"Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer","volume":"173","author":"Vallet","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"issue":"3","key":"10.1016\/j.bcp.2025.117532_b0470","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1158\/1535-7163.MCT-12-0767","article-title":"A novel small-molecule inhibitor of mcl-1 blocks pancreatic cancer growth in vitro and in vivo","volume":"13","author":"Abulwerdi","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bcp.2025.117532_b0475","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ejmech.2018.10.003","article-title":"Structure-guided design of pyridoclax derivatives based on Noxa\/Mcl-1 interaction mode","volume":"159","author":"Hedir","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117532_b0480","unstructured":"Lee T, Bian Z, Zhao B, Hogdal LJ, Sensintaffar JL, Goodwin CM, et al. Discovery and Biological Characterization of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors."},{"issue":"12","key":"10.1016\/j.bcp.2025.117532_b0485","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1158\/2159-8290.CD-18-0140","article-title":"A novel MCL1 inhibitor combined with venetoclax rescues venetoclax-resistant acute myelogenous leukemia","volume":"8","author":"Ramsey","year":"2018","journal-title":"Cancer Discov."},{"issue":"8","key":"10.1016\/j.bcp.2025.117532_b0490","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1021\/acs.jmedchem.8b01991","article-title":"Discovery of potent myeloid cell leukemia-1 (Mcl-1) inhibitors that demonstrate in vivo activity in mouse xenograft models of human cancer","volume":"62","author":"Lee","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117532_b0495","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113546","article-title":"NA1\u2014115\u20147, from Zygogynum pancheri, is a new selective MCL-1 inhibitor inducing the apoptosis of hematological cancer cells but non-toxic to normal blood cells or cardiomyocytes","volume":"154","author":"Daressy","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bcp.2025.117532_b0500","article-title":"Abstract LB_A01: Rapidly cleared MCL1 inhibitor TTX-810 showing robust efficacy in preclinical tumor models with no effects on cardiomyocytes in vitro and in vivo","volume":"22(12_Supplement):LB_A01-LB_A","author":"Rauh","year":"2023","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bcp.2025.117532_b0505","article-title":"BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models","volume":"1\u201315","author":"Rauh","year":"2024","journal-title":"Nature Cancer."},{"key":"10.1016\/j.bcp.2025.117532_b0510","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1436786","article-title":"KS18, a Mcl-1 inhibitor, improves the effectiveness of bortezomib and overcomes resistance in refractory multiple myeloma by triggering intrinsic apoptosis","volume":"15","author":"Al-Odat","year":"2024","journal-title":"Front. Pharmacol."},{"issue":"7","key":"10.1016\/j.bcp.2025.117532_b0515","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1128\/JB.181.7.2166-2174.1999","article-title":"Characterization of the pyoluteorin biosynthetic gene cluster of Pseudomonas fluorescens Pf-5","volume":"181","author":"Nowak-Thompson","year":"1999","journal-title":"J. Bacteriol."},{"key":"10.1016\/j.bcp.2025.117532_b0520","article-title":"Pyoluteorin derivatives induce Mcl-1 degradation and apoptosis in hematological cancer cells","volume":"15(12):1688-99","author":"Doi","year":"2014","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.bcp.2025.117532_b0525","first-page":"1217","article-title":"Therapeutic Efficacy of Mcl-1 Antagonism in Large Granular Lymphocyte Leukemia","volume":"130","author":"LeBlanc","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2025.117532_b0530","doi-asserted-by":"crossref","first-page":"5771","DOI":"10.1182\/blood-2023-187613","article-title":"Drug Resistance can be Overcome in Multiple Myeloma and Acute Myeloid Leukemia by Targeting Mcl-1 with the Small Chemical KS18","volume":"142","author":"Al-Odat","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2025.117532_b0535","article-title":"KS18, an Mcl-1 inhibitor, triggers cell death and enhances the therapeutic efficacy of venetoclax in bortezomib-resistant multiple myeloma cells","volume":"84(6_Supplement):4670-","author":"Odat","year":"2024","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.bcp.2025.117532_b0540","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1158\/2159-8290.CD-18-0387","article-title":"AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies","volume":"8","author":"Caenepeel","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bcp.2025.117532_b0545","article-title":"Discovery and preclinical evaluation of AMG 397, a potent, selective and orally bioavailable MCL1 inhibitor","volume":"80(16_Supplement):6218-","author":"Caenepeel","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2025.117532_b0550","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.critrevonc.2017.05.010","article-title":"Azacitidine in adult patients with acute myeloid leukemia","volume":"116","author":"Schuh","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.bcp.2025.117532_b0555","doi-asserted-by":"crossref","first-page":"6875","DOI":"10.2147\/OTT.S223119","article-title":"Inhibition of the hedgehog pathway for the treatment of cancer using Itraconazole","author":"Li","year":"2019","journal-title":"OncoTargets and Therapy."},{"issue":"22","key":"10.1016\/j.bcp.2025.117532_b0560","doi-asserted-by":"crossref","first-page":"15562","DOI":"10.1021\/acs.joc.3c00939","article-title":"Enabling, Decagram-Scale Synthesis of Macrocyclic MCL-1 Inhibitor ABBV-467","volume":"88","author":"Brady","year":"2023","journal-title":"J. Org. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2025.117532_b0565","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s43856-023-00380-z","article-title":"Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patients","volume":"3","author":"Yuda","year":"2023","journal-title":"Communications Medicine."},{"issue":"7626","key":"10.1016\/j.bcp.2025.117532_b0570","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature19830","article-title":"The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models","volume":"538","author":"Kotschy","year":"2016","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.bcp.2025.117532_b0575","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.3324\/haematol.2018.212308","article-title":"Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma","volume":"105","author":"Algar\u00edn","year":"2020","journal-title":"Haematologica"},{"issue":"22","key":"10.1016\/j.bcp.2025.117532_b0580","doi-asserted-by":"crossref","first-page":"13762","DOI":"10.1021\/acs.jmedchem.0c01234","article-title":"Discovery of S64315, a potent and selective Mcl-1 inhibitor","volume":"63","author":"Szlavik","year":"2020","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bcp.2025.117532_b0585","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1021\/acsmedchemlett.6b00464","article-title":"Structure based design of non-natural peptidic macrocyclic Mcl-1 inhibitors","volume":"8","author":"Johannes","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bcp.2025.117532_b0590","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1182\/blood-2018-99-113504","article-title":"Preclinical activity of novel MCL1 inhibitor AZD5991 in multiple myeloma","volume":"132","author":"Matulis","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bcp.2025.117532_b0595","doi-asserted-by":"crossref","first-page":"5341","DOI":"10.1038\/s41467-018-07551-w","article-title":"Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia","volume":"9","author":"Tron","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2025.117532_b0600","article-title":"Preclinical characterization of PRT1419, a potent, selective and orally available inhibitor of MCL1","volume":"81(13_Supplement):983-","author":"Bhagwat","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2025.117532_b0605","article-title":"Abstract CT172: a phase 1, open-label, dose-escalation study of PRT1419, a selective induced myeloid leukemia cell differentiation protein (MCL-1) inhibitor, in patients (pts) with advanced\/metastatic solid tumors","volume":"83(8_Supplement):CT172-CT","author":"Falchook","year":"2023","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.bcp.2025.117532_b0610","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.3324\/haematol.2020.252130","article-title":"Inhibition of the anti-apoptotic protein MCL-1 severely suppresses human hematopoiesis","volume":"106","author":"Bohler","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.bcp.2025.117532_b0615","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.taap.2018.09.041","article-title":"Role of Mcl-1 in regulation of cell death in human induced pluripotent stem cell-derived cardiomyocytes in vitro","volume":"360","author":"Guo","year":"2018","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"8","key":"10.1016\/j.bcp.2025.117532_b0620","doi-asserted-by":"crossref","first-page":"5963","DOI":"10.1021\/acs.jmedchem.3c01998","article-title":"Targeting myeloid leukemia-1 in cancer therapy: advances and directions","volume":"67","author":"Deng","year":"2024","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bcp.2025.117532_b0625","doi-asserted-by":"crossref","first-page":"e1595","DOI":"10.1002\/wsbm.1595","article-title":"Intracellular and microenvironmental regulation of mitochondrial membrane potential in cancer cells","volume":"15","author":"Begum","year":"2023","journal-title":"WIREs Mech. Dis."},{"key":"10.1016\/j.bcp.2025.117532_b0630","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2022.101512","article-title":"Nanoparticle-based medicines in clinical cancer therapy","volume":"45","author":"Wang","year":"2022","journal-title":"Nano Today"},{"issue":"18","key":"10.1016\/j.bcp.2025.117532_b0635","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.2165\/11207510-000000000-00000","article-title":"Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi\u2019s sarcoma","volume":"71","author":"Duggan","year":"2011","journal-title":"Drugs"},{"issue":"43","key":"10.1016\/j.bcp.2025.117532_b0640","doi-asserted-by":"crossref","first-page":"9573","DOI":"10.1002\/adma.201603463","article-title":"Engineered Nano-Platelets for Enhanced Treatment of Multiple Myeloma and Thrombus","volume":"28","author":"Hu","year":"2016","journal-title":"Advanced Materials (deerfield Beach, Fla)."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000629522500797X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000629522500797X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T20:12:13Z","timestamp":1781122333000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000629522500797X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":128,"alternative-id":["S000629522500797X"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117532","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Saga of MCL1 inhibitors in multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117532","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117532"}}